COVID-19 (SARS-CoV-2 Infection) in Lymphoma Patients: A Review

Overview

Journal World J Virol

Publisher Baishideng Publishing Group

Date 2021 Dec 15

PMID 34909405

Citations 21

Authors

Valentina Bonuomo

Isacco Ferrarini

Michele DellEva

Eugenio Sbisa

Mauro Krampera

Carlo Visco

Affiliations

Soon will be listed here.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection now has a global resonance and represents a major threat for several patient populations. Observations from initial case series suggested that cancer patients in general might have an unfavorable outcome following coronavirus disease 2019 (COVID-19), due to their underlying conditions and cytotoxic treatments. More recently, data regarding the incidence and clinical evolution of COVID-19 in lymphomas have been reported with the aim to identify those more frequently associated with severe complications and death. Patients with lymphoma appear particularly vulnerable to SARS-CoV-2 infection, only partly because of the detrimental effects of the anti-neoplastic regimens (chemotherapy, pathway inhibitors, monoclonal antibodies) on the immune system. Here, we systematically reviewed the current literature on COVID-19 in adult patients with lymphoma, with particular emphasis on disease course and prognostic factors. We also highlighted the potential differences in COVID-19 clinical picture according to lymphoma subtype, delivered treatment for the hematological disease and its relationship on how these patients have been managed thus far.

Citing Articles

Virological Aspects of COVID-19 in Patients with Hematological Malignancies: Duration of Viral Shedding and Genetic Analysis.

Themlaoui A, Ancora M, Ghedira K, Mhalla Y, Hamdoun M, Bahri M Viruses. 2025; 17(1).

PMID: 39861838 PMC: 11768452. DOI: 10.3390/v17010046.

COVID-19 and Oncofertility: No SARS-CoV-2 in Semen but Inflammation Seems to Affect Sperm Parameters.

Chaput L, Pons-Rejraji H, Chabrolles H, Fiot M, Lucas C, Pereira B J Med Virol. 2024; 96(12):e70070.

PMID: 39648939 PMC: 11626501. DOI: 10.1002/jmv.70070.

COVID-19 infection in children with blood cancer: A systematic review.

Alhumaid S, Al Noaim K, Almuslim A, Turkistani J, Alqurini Z, Alshakhs A Ann Hematol. 2024; .

PMID: 39496811 DOI: 10.1007/s00277-024-06057-4.

Oncogenic potential of SARS-CoV-2-targeting hallmarks of cancer pathways.

Jaiswal A, Shrivastav S, Kushwaha H, Chaturvedi R, Singh R Cell Commun Signal. 2024; 22(1):447.

PMID: 39327555 PMC: 11426004. DOI: 10.1186/s12964-024-01818-0.

Managing and treating COVID-19 in patients with hematological malignancies: a narrative review and expert insights.

Ng H, Alata M, Nguyen Q, Huynh Duc Vinh P, Tan J, Wong C Clin Exp Med. 2024; 24(1):119.

PMID: 38833206 PMC: 11150206. DOI: 10.1007/s10238-024-01381-5.

References

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J . Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708-1720. PMC: 7092819. DOI: 10.1056/NEJMoa2002032. View

ODriscoll M, Ribeiro Dos Santos G, Wang L, Cummings D, Azman A, Paireau J . Age-specific mortality and immunity patterns of SARS-CoV-2. Nature. 2020; 590(7844):140-145. DOI: 10.1038/s41586-020-2918-0. View

Otsuka Y, Kobayashi T . Case Report: A Patient with COVID-19 under Myelosuppression Induced by Chemotherapy. Am J Trop Med Hyg. 2020; 103(5):1983-1985. PMC: 7646807. DOI: 10.4269/ajtmh.20-0678. View

Mandala M, Lorigan P, De Luca M, Bianchetti A, Merelli B, Cecilia Bettini A . SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study. J Immunother Cancer. 2021; 9(2). PMC: 7887862. DOI: 10.1136/jitc-2020-001694. View

Cattaneo C, Daffini R, Pagani C, Salvetti M, Mancini V, Borlenghi E . Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19. Cancer. 2020; 126(23):5069-5076. DOI: 10.1002/cncr.33160. View

Laurenge A, Ursu R, Houillier C, Abdi B, Tebano G, Quemeneur C . SARS-CoV-2 infection in patients with primary central nervous system lymphoma. J Neurol. 2021; 268(9):3072-3080. PMC: 7776286. DOI: 10.1007/s00415-020-10311-w. View

Klebanov N, Pahalyants V, Murphy W, Theodosakis N, Zubiri L, Klevens R . Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors. Oncologist. 2021; 26(5):e898-e901. PMC: 8100539. DOI: 10.1002/onco.13768. View

Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L . CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011; 12(11):1013-22. DOI: 10.1016/S1470-2045(11)70235-2. View

Lamure S, Dulery R, Di Blasi R, Chauchet A, Laureana C, Deau-Fischer B . Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study. EClinicalMedicine. 2020; 27:100549. PMC: 7550257. DOI: 10.1016/j.eclinm.2020.100549. View

10.

Fujii H, Tsuji T, Sugitani M, Matsumoto Y, Yuba T, Tanaka S . Prolonged persistence of SARS-CoV-2 infection during A+AVD therapy for classical Hodgkin's lymphoma: A case report. Curr Probl Cancer. 2021; 45(6):100739. PMC: 7988448. DOI: 10.1016/j.currproblcancer.2021.100739. View

11.

Martin-Moro F, Marquet J, Piris M, Michael B, Saez A, Corona M . Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies. Br J Haematol. 2020; 190(1):e16-e20. PMC: 7267398. DOI: 10.1111/bjh.16801. View

12.

Regalado-Artamendi I, Jimenez-Ubieto A, Hernandez-Rivas J, Navarro B, Nunez L, Alaez C . Risk Factors and Mortality of COVID-19 in Patients With Lymphoma: A Multicenter Study. Hemasphere. 2021; 5(3):e538. PMC: 7886434. DOI: 10.1097/HS9.0000000000000538. View

13.

Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z . Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov. 2020; 10(6):783-791. PMC: 7309152. DOI: 10.1158/2159-8290.CD-20-0422. View

14.

Fox T, Troy-Barnes E, Kirkwood A, Chan W, Day J, Chavda S . Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo- or immunotherapy. Br J Haematol. 2020; 191(2):194-206. PMC: 7405103. DOI: 10.1111/bjh.17027. View

15.

Yonal-Hindilerden I, Hindilerden F, Mastanzade M, Tiryaki T, Tasan-Yenigun S, Bilen Y . Case Report: Severe COVID-19 Pneumonia in a Patient With Relapsed/Refractory Hodgkin's Lymphoma. Front Oncol. 2021; 11:601709. PMC: 8013978. DOI: 10.3389/fonc.2021.601709. View

16.

Infante M, Gonzalez-Gascon Y Marin I, Munoz-Novas C, Churruca J, Foncillas M, Landete E . COVID-19 in patients with hematological malignancies: A retrospective case series. Int J Lab Hematol. 2020; 42(6):e256-e259. PMC: 7435496. DOI: 10.1111/ijlh.13301. View

17.

Biernat M, Kolasinska A, Kwiatkowski J, Urbaniak-Kujda D, Biernat P, Janocha-Litwin J . Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19. Viruses. 2021; 13(3). PMC: 8001057. DOI: 10.3390/v13030436. View

18.

Pasin F, Mascalchi Calveri M, Calabrese A, Pizzarelli G, Bongiovanni I, Andreoli M . Oncolytic effect of SARS-CoV2 in a patient with NK lymphoma. Acta Biomed. 2020; 91(3):ahead of print. PMC: 7716983. DOI: 10.23750/abm.v91i3.10141. View

19.

Wood W, Neuberg D, Thompson J, Tallman M, Sekeres M, Sehn L . Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. Blood Adv. 2020; 4(23):5966-5975. PMC: 7724912. DOI: 10.1182/bloodadvances.2020003170. View

20.

Velier M, Priet S, Appay R, Atieh T, Lepidi H, Kaplanski G . Severe and Irreversible Pancytopenia Associated With SARS-CoV-2 Bone Marrow Infection in a Patient With Waldenstrom Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2021; 21(6):e503-e505. PMC: 7832621. DOI: 10.1016/j.clml.2021.01.005. View